2025-12-31 - Analysis Report
Okay, here's a comprehensive analysis of Natera Inc. (NTRA) based on the provided data, broken down into the requested sections:

**0) Report Structure:**

*   First, raw numbers are presented from the provided data.
*   Then, a simple analysis is provided for each section, drawing conclusions from the numbers.
*   Finally, a comprehensive summary ties all the sections together.

**1) Return Rate vs. S&P 500 (VOO):**

*   **Ticker:** NTRA
*   **Company:** Natera Inc. - A genetic testing company focused on non-invasive prenatal testing (NIPT) and cancer screening.
*   **NTRA Cumulative Return:** 135.64%
*   **VOO Cumulative Return:** 102.47%
*   **Divergence:** 36.0 (Relative Divergence: 47.3)

**Analysis:**

NTRA has significantly outperformed the S&P 500 (VOO) in cumulative return. The current divergence of 36.0 suggests NTRA is performing 36.0% better than VOO, which is at 47.3 percentile over min/max divergence range, or right in the middle of its min/max divergence range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR      | MDD   | Alpha    | Beta   | Cap(B) |
|------------|-----------|-------|----------|--------|--------|
| 2015-2017  | -10.0%    | 70.1% | -34.0%   | -0.2   | 1.2    |
| 2016-2018  | 22.0%     | 80.0% | 6.0%     | 0.1    | 1.9    |
| 2017-2019  | 50.0%     | 80.0% | 28.0%    | 1.0    | 4.7    |
| 2018-2020  | 186.0%    | 80.5% | 163.0%   | 1.1    | 13.9   |
| 2019-2021  | 96.0%     | 80.5% | 49.0%    | 1.6    | 13.0   |
| 2020-2022  | -77.0%    | 80.5% | -76.0%   | 0.1    | 5.6    |
| 2021-2023  | -194.0%   | 76.6% | -195.0%  | -1.1   | 8.7    |
| 2022-2024  | 8.0%      | 76.6% | -13.0%   | -1.2   | 22.1   |
| 2023-2025  | 163.0%    | 76.6% | 96.0%    | 0.1    | 32.1   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate varies significantly, showing high volatility with periods of substantial growth (186%, 163%, 96%) and steep declines (-194%, -77%, -10%).
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant risk and price swings, especially from 2016 to 2022, where it consistently reached around 80%.
*   **Alpha:** Alpha measures the stock's performance relative to the market (S&P 500).  NTRA demonstrates substantial outperformance during some periods (e.g., 2018-2020), and significant underperformance in others (2021-2023).
*   **Beta:** Beta measures the stock's volatility relative to the market. NTRA's Beta fluctuates, ranging from negative to positive, indicating varying degrees of correlation with the market. The negative beta observed from 2022-2024 indicates an inverse relationship with the market index.
*   **Cap(B):** This is the implied market capitalization in Billions of Dollars. The company's market cap has fluctuated significantly over the years.

**2) Recent Stock Price Fluctuations:**

*   **Close Price:** 229.98
*   **Previous Close:** 231.30
*   **Change:** -0.57
*   **5-day SMA:** 233.192
*   **20-day SMA:** 233.6335
*   **60-day SMA:** 210.6322

**Analysis:**

*   The stock price closed slightly down from the previous day.
*   The 5-day and 20-day Simple Moving Averages (SMAs) are very close, suggesting short-term price stability.
*   The 60-day SMA is significantly lower than the 5-day and 20-day SMAs, indicating that the stock price has been trending upwards in the recent two months.

**3) RSI, PPO, and Divergence Analysis:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 40.53
*   **PPO:** -0.681
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 2.0 (+): 단기상승 (Short-term rise)
*   **Expected Return (%):** -49.9% (Long-term excess return compared to S&P 500)

**Analysis:**

*   **MRI:** A high MRI suggests a favorable market environment for investment.
*   **RSI:** An RSI of 40.53 indicates that the stock is neither overbought nor oversold, and it is trending towards the oversold.
*   **PPO:** A negative PPO suggests that short term moving average is below longer term moving average (bearish but potentially turning towards bullish with a convergence of moving averages).
*   **Hybrid Signal:** The "Buy" signal with a 0% cash ratio suggests a strong recommendation to invest fully in the stock.
*   **Recent Divergence Change:** A positive divergence change indicates the stock has been outperforming the S&P 500 recently.
*   **Expected Return:** The negative expected return indicates that long-term investment is expected to underperform against the S\&P 500.

**4) Recent News & Significant Events:**

*   **Bullish Analyst Sentiment:** Multiple articles highlight bullish analyst ratings and price target increases (Barclays, The Globe and Mail).
*   **Institutional Buying:** Reports indicate that SWS Partners and potentially other investors are buying NTRA shares (MarketBeat, 24/7 Wall St. - Stanley Druckenmiller's investment).
*   **Positive Price Momentum:** Some articles mention recent gains and technical buy points (Investor's Business Daily).
*   **Investor Confidence:** Articles suggest that prominent investors are adding NTRA to their portfolios (Yahoo Finance - This Investor Beat the Market...).

**Analysis:**

Recent news sentiment is generally positive, driven by analyst upgrades, institutional buying, and some positive price momentum. The news suggests increasing confidence in the company's future prospects.

**4-2) Analyst Opinions:**

*   **Consensus:** Strong Buy (Mean: 1.47)
*   **Opinions:** 19
*   **Target Price:** Avg: 246.26 / High: 285.00 / Low: 186.00
*   **Recent Rating Changes:** No changes specified.

**Analysis:**

The analyst consensus is strongly bullish on NTRA, with a high average target price, suggesting significant upside potential. The lack of recent rating changes, positive news may indicate that the trend may continue.

**5) Recent Earnings Analysis:**

| 날짜        | EPS   | 매출      |
|-------------|-------|-----------|
| 2025-11-07 | -0.64 | 0.59 B$   |
| 2025-08-08 | -0.74 | 0.55 B$   |
| 2025-05-09 | -0.5  | 0.50 B$   |
| 2024-11-12 | -0.26 | 0.44 B$   |
| 2025-11-07 | -0.26 | 0.44 B$   |

**Analysis:**

*   **EPS:**  Natera is not yet profitable, as EPS is negative in all reported quarters. EPS losses narrowed from 2024-11-12 through 2025-05-09, but have since widened again.
*   **Revenue:** Revenue is steadily increasing each quarter, indicating growth in the company's sales.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30 | $0.59B  | 64.91%        |
| 2025-06-30 | $0.55B  | 63.41%        |
| 2025-03-31 | $0.50B  | 63.12%        |
| 2024-12-31 | $0.48B  | 62.94%        |
| 2024-09-30 | $0.44B  | 61.79%        |

**Capital and Profitability:**

| Quarter      | Equity | ROE      |
|--------------|--------|----------|
| 2025-09-30 | $1.25B | -6.99%   |
| 2025-06-30 | $1.25B | -8.10%   |
| 2025-03-31 | $1.24B | -5.40%   |
| 2024-12-31 | $1.20B | -4.50%   |
| 2024-09-30 | $0.88B | -3.60%   |

**Analysis:**

*   **Revenue:** Consistent growth in quarterly revenue confirms business expansion.
*   **Profit Margin:** High and relatively stable profit margins indicate the company is managing its costs effectively.
*   **Equity:** Equity has increased significantly, indicating increased capital.
*   **ROE:** Negative ROE values reflect the company's ongoing losses, despite revenue growth. The ROE worsening over the last two quarters suggests that the losses are growing faster than the book value.

**7) Comprehensive Analysis (Summary):**

Natera (NTRA) is a high-growth, high-risk stock with significant potential but also considerable volatility.

*   **Strengths:** Strong revenue growth, high profit margins, positive analyst sentiment, and institutional buying are significant positives. The stock has outperformed the S&P 500 historically, and there is positive short-term price momentum.
*   **Weaknesses:** The company is currently unprofitable with negative EPS and ROE. The stock has a history of wild price swings (high MDD and volatile CAGR, Alpha, and Beta). Despite short-term positive relative divergence, long term investment is expected to underperform the S&P 500.
*   **Outlook:** The analyst consensus and recent news events suggest a potentially favorable outlook. The strong "Buy" signal may mean the analyst thinks that the increase in capital and consistent revenue growth will offset the current financial situation.

**Overall Recommendation:**

Based on the analysis, NTRA appears to be a speculative investment. The MRI of 0.9 suggests that this is a suitable time to invest in the stock, but the analysis clearly demonstrates the volatility. It is important to monitor the company's financial performance, particularly its path to profitability, to make informed investment decisions.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.